Astra To Continue Pulmicort Manufacturing Talks With FDA
Executive Summary
Astra is in discussions with FDA regarding "restrictive manufacturing specifications" applying to the firm's dry powder inhaled asthma therapy Pulmicort Turbuhaler, the company said.
You may also be interested in...
AstraZeneca's Pulmicort Posts $65 Mil. In Nine-Month U.S. Sales
AstraZeneca's dry powder inhaled asthma therapy Pulmicort Turbuhaler posted nine-month sales of $65 mil. in the U.S., suggesting that the impact of supply constraints imposed by FDA may be beginning to ease, CEO Tom McKillop reported during an Oct. 28 teleconference on third quarter financial results.
AstraZeneca's Pulmicort Posts $65 Mil. In Nine-Month U.S. Sales
AstraZeneca's dry powder inhaled asthma therapy Pulmicort Turbuhaler posted nine-month sales of $65 mil. in the U.S., suggesting that the impact of supply constraints imposed by FDA may be beginning to ease, CEO Tom McKillop reported during an Oct. 28 teleconference on third quarter financial results.
AstraZeneca Sales Restructuring To Stimulate Respiratory Area, CEO Says
AstraZeneca's sales and marketing restructuring should stimulate growth in the company's respiratory drug portfolio, CEO Tom McKillop maintained during an Aug. 3 briefing in London.